Aier Eye Hospital Group Co., Ltd. Class A

Aier Eye Hospital Group Co., Ltd. Class A

SSZSE:300015
9.15
CNY
+0.16
(+1.78%)
0.29EPS
30.61P/E
74.06BMarket Cap
Apr 23Next Earn
Aier Eye Hospital Group Co., Ltd. Class A
SZSE:300015
(Shenzhen Stock Exchange)

Recent

price

9.15

P/E

ratio

30.61

div

yld

2.09%

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
CNY
0.14
0.21
0.27
0.32
0.39
0.51
0.62
0.91
1.18
1.48
1.73
1.66
1.78
2.21
2.27
2.41
2.5
Revenue per Share
0.02
0.03
0.03
0.04
0.05
0.07
0.09
0.11
0.15
0.2
0.25
0.26
0.28
0.36
0.38
0.35
0.26
Basic EPS, GAAP
- -
- -
0.01
0.03
0.04
0.04
0.06
0.11
0.09
0.2
0.36
0.29
0.34
0.48
0.33
0.42
- -
Free Cash Flow per Basic Share
0.01
0.01
0.01
0.01
0.01
0.02
0.05
0.03
0.08
0.08
0.08
0.07
0.07
0.08
0.15
0.16
0.19
Dividend per Share
0.16
0.17
0.19
0.21
0.24
0.29
0.36
0.59
0.65
0.75
1.09
1.24
1.79
2.02
2.22
2.36
2.44
Book Value per Share
0.15
0.15
0.16
0.17
0.21
0.23
0.27
0.29
0.35
0.39
0.6
0.68
1.11
1.23
1.22
1.23
1.26
Tangible Book Value per Share
6,186
6,188
6,111
6,242
6,193
6,235
6,450
6,547
6,771
6,773
6,868
9,054
9,047
9,218
9,244
9,268
9,295
Basic Weighted Avg Shares
865
1,311
1,640
1,985
2,402
3,166
4,000
5,963
8,009
9,990
11,912
15,001
16,110
20,367
20,983
22,353
23,213
Sales/Revenue/Turnover
19.23
18.09
15.49
16.73
17.57
18.97
17.45
19.41
22.22
24.24
28.89
28.16
24.96
27.24
22.81
21.91
22.69
Operating Margin (%)
56
76
98
111
115
123
143
197
263
352
416
952
1,166
1,347
1,594
1,779
- -
Depreciation Expense
120
172
183
223
309
428
557
743
1,009
1,379
1,724
2,323
2,524
3,359
3,556
3,240
2,423
Net Income, GAAP
30.51
28.42
26.11
28.07
23.14
20.65
17.13
22.82
22.78
22.23
20.57
21.53
19.37
19.67
18.68
21.51
39.04
Effective Tax Rate (%)
13.91
13.12
11.13
11.26
12.87
13.52
13.92
12.45
12.6
13.8
14.47
15.49
15.67
16.49
16.95
14.5
10.44
Profit Margin (%)
740
629
523
638
773
894
648
1,561
1,198
1,148
2,025
939
4,288
4,175
3,001
1,940
3,091
Working Capital
64
64
- -
- -
- -
174
186
1,467
1,320
1,636
3,958
3,155
3,443
3,982
4,565
4,855
4,578
LT Debt
1,309
1,413
1,569
1,739
2,061
2,499
3,209
5,472
5,969
7,023
10,652
12,224
17,615
20,025
21,812
23,398
24,423
Total Equity
8.74
11.88
11.77
13.49
17.19
19.99
18.97
16.03
16
18.12
16.73
16.36
14.31
16.66
14.5
12.2
- -
Return on Invested Capital (%)
8.91
12.27
11.94
13.62
16.08
17.57
18.15
13.46
13.34
16.02
12.94
13.83
12.55
13.47
13.22
10.87
- -
Return on Capital (%)
9.68
13
12.74
14.12
16.92
19.53
20.45
17.96
18.5
22.45
20.96
21.96
18.04
18.91
17.97
15.18
- -
Return on Common Equity (%)

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
2,522
3,073
3,144
LT Borrowings
178
181
187
LT Finance Leases
4,540
4,417
4,390
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
9,325
9,325
9,281
Market Capitalization
88,685
77,028
74,062

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
10,099
10,280
10,749
Cash, Cash Equivalents & STI
6,417
6,718
6,714
Accounts Receivable, Net
1,964
1,922
2,138
Inventories
1,050
978
1,055
Total Current Liabilities
6,995
6,952
7,659
Payables & Accruals
- -
- -
- -
ST Debt
2,522
3,073
3,144
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
26.61%
17.75%
7.27%
Free Cash Flow
39.43%
12.81%
27.15%
Net Income, GAAP
23.45%
14.7%
-8.88%
Sales/Revenue/Turnover
22.3%
13.86%
6.53%
Total Cash Common Dividend
47.67%
26.98%
7.48%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
5,196
5,349
5,756
4,681
20,983
2025
6,026
5,481
- -
4,869
22,353
2026
6,396
5,549
6,399
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.1
0.12
0.15
0.01
0.38
2025
0.11
0.11
- -
0.01
0.35
2026
0.13
0.02
0.1
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
0.15
0.01
-0.01
0.15
2025
- -
0.17
- -
- -
0.16
2026
0.08
- -
0.11
- -
- -
Business
Aier Eye Hospital Group Co., Ltd. (300015.SZ) operates as China's largest provider of ophthalmology chain medical services, principally engaged in the diagnosis and treatment of various ophthalmic diseases, surgical services, and medical optometry; core offerings encompass refractive surgery including myopia correction, cataract surgery, anterior segment surgery such as glaucoma and corneal treatments, posterior segment surgery for fundus diseases, pediatric ophthalmology, optometry services, eyeglasses, and specialized treatments for lacrimal pathology, ocular surface conditions, and eye contouring aesthetics. Founded in 2002 or 2003 and headquartered in Changsha, Hunan province, the company manages an extensive global network of over 900 eye hospitals, centers, and clinics, including approximately 800 in mainland China, 8-9 in Hong Kong, 1 in the United States, more than 100 in Europe, and 14-18 in Southeast Asia, serving patients across Asia, Europe, and North America through subsidiaries such as Clínica Baviera S.A. (listed in Spain as CBAV.MC), ISEC Healthcare Ltd. (listed in Singapore as 40T), MING WANG Eye Center, and Hong Kong Asia Medical. In recent developments, Aier has pursued aggressive expansion via acquisitions, including in July 2024 the purchase of equity stakes in 35 mainland China institutions such as Humen Aier and Yuncheng Aier for CNY 898 million and in May 2024 stakes in 52 others including Chongqing Eye Optometry for CNY 1.344 billion; through its European arm Clínica Baviera, it acquired the UK's Optimax Group (Eye Hospitals Group) in 2024 for approximately €22.75 million to enter the UK market; and in October 2025, it invested in Sichuan Cunde Therapeutics Co., Ltd. as part of a Series A round, alongside additional deals like a 70% stake in Xiangshan Aier Eye Hospital in December 2023 and stakes in Tongren Aier Renai Eye Hospital in August 2025. These moves, which added over 149 subsidiaries to its consolidation scope by end-2024, bolster its domestic dominance and international footprint amid a strategy emphasizing innovation-driven growth and global ophthalmology leadership.